BMS-986340 drug page Clinical trials

Trials with BMS-986340

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

2Trials
1Recruiting
8Countries
1.116Planned patients

Showing 1–2 of 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Recruiting Phase 1 1.109 patients NCT04895709

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…

United States, Australia, Canada, Germany and 4 more May 2021 – Aug 2031 Interventional
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
Finished Phase 2 7 patients NCT07011550

To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.

United States Aug 2025 – Jul 2030 Interventional

Where the recruiting trials are